Naveen Gullapalli has been appointed as Managing Director of Amgen's India Technology and Innovation Hub in Hyderabad, ...

Amgen appointed Naveen Gullapalli, former Novartis executive, as Managing Director of Amgen India. Gullapalli will lead Amgen ...

Gullapalli will oversee the Amgen India Technology and Innovation hub, leveraging his extensive expertise in global ...

Amgen appoints Naveen Gullapalli as managing director to accelerate tech & innovation from India: Our Bureau, Bengaluru ...

Kochi: CPM state secretary MV Govindan said on Wednesday that there was no need for a CBI probe in Naveen Babu's case and added that a CBI probe is not the final word in such matters. The former ...

Manjusha for a CBI probe into the death of her husband, Kannur Additional District Magistrate Naveen Babu, who was found hanging at his official residence. After a preliminary hearing, the court ...

Amgen Dives 5% Despite 'Truly Remarkable' Results For Obesity Treatment Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

Shares of Amgen (NASDAQ:AMGN) have recently been under pressure due to the increasing focus on the highly anticipated phase 2 readout of MariTide in obese and type 2 diabetes patients. Last week ...

Amgen reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and potential Ozempic competitor MariTide, however, Wall Street wasn’t very impressed.

As Amgen (NASDAQ:AMGN) shares are down 9% following the release of highly anticipated phase 2 data on its weight loss drug MariTide, Street analysts are weighing in. And there's a theme ...

Amgen said its experimental weight loss injection helped patients lose up to 20% of their weight on average after a year, with no plateau, in a critical mid-stage trial. But shares of Amgen fell ...